Conditions: Onychomycosis Dermatophytosis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 19
Healthy volunteers: yes

Brief summary:
This study will examine how Jublia affects dermatophytomas, which are difficult to treat with other therapeutic options.

Detailed description:
Dermatophytomas are known to be resistant to even long courses of systemic antifungals, and have therefore been excluded from both topical and systemic clinical trials for onychomycosis, including those for Efinaconazole solution. Efinaconazole (Jublia) 10% solution is an FDA approved topical medication indicated for treatment of distal lateral subungual onychomycosis (DLSO), and the utility of this medication likely exceeds published results. Efinaconazole solution's novel ability to penetrate into the subungual space likely accounts for improved treatment results seen in DLSO treated with Jublia. We will investigate the utility of topical efinaconazole solution in the treatment of dermatophytomas.

Arms:
arm 1: Subjects with distal lateral subungual onychomycosis (DLSO) with dermatophytoma.

Interventions: intervention 1: Jublia (Efinaconazole 10% Topical Solution)
Intervention descriptions: intervention 1: Efinaconazole 10% Topical Solution will be applied to the great toenail with the DLSO and dermatophytoma.

Protocol document:
Prot_SAP_000.pdf: